← All organizations

CAR-T (Shanghai) Biotechnology Co.,Ltd.

Government

Also known as: CAR-T (Shanghai) Biotechnology Co., Ltd. | CAR-T (Shanghai) Biotechnology Co.,Ltd. | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

Last known activity

Jan 1, 2022

Timeline

No events for the selected filters.

Drugs by trial phase (5 distinct, 6 trials)

Phase 2 (1 own, 0 via acquisition)

autologous tumor infiltrating lymphocytes

Phase 1 (3 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

fluoxetine

Indications

Studied for

Recent trials (6)

NCT05127369Lead sponsorN/AJan 1, 2022
NCT04538313Lead sponsorPhase 1/Phase 2Aug 26, 2020
NCT04302519Lead sponsorEarly Phase 1Mar 5, 2020
NCT04130100Lead sponsorEarly Phase 1Apr 4, 2019
NCT03912480Lead sponsorEarly Phase 1Jan 5, 2019
NCT03658655Lead sponsorEarly Phase 1Jun 1, 2018

Details

Last known activity: Jan 1, 2022